tbuckley/cabot-search huggingface dataset:
Die Chirurgie: Eine zusammenfassende Darstellung der allgemeinen und der speziellen Chirurgie.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vasodilator therapy for chronic congestive heart failure
Authors: J. Abrams
Journal: JAMA (1985)

THE USE of vasodilators as adjunctive therapy for congestive heart failure was first popularized over ten years ago by the work of Parmley, Chatterjee, Cohn, and Franciosa, although occasional clinical investigative reports using vasodilators date back to the 1950s and even earlier. Physicians have had considerable experience with vasodilators, yet important questions remain unanswered regarding the ultimate role of this therapeutic approach to the failing heart. This review will focus on the present status of the currently available vasodilators (nitrates, hydralazine hydrochloride, prazosin hydrochloride, and captopril) in the management of chronic congestive heart failure. <h3>THE CONCEPT OF VASODILATOR THERAPY Afterload or Impedance Reduction</h3> <i>Afterload</i>, a term derived from isolated cardiac muscle experiments, is best defined as the forces opposing left ventricular fiber shortening during ejection.<i>Impedance</i>, a term preferred by many investigators, is the instantaneous resistance to flow to the contracting left ventricle and is equivalent to instantaneous left ventricular
Abstract 3419: Sex, mutations, and mortality in early stage melanoma
Authors: Matthew R. Schwartz, Li Luo, Marianne Berwick
Journal: Cancer Research (2019)

Abstract Our goal is to investigate the relationship between sex, tumor mutation burden (TMB) and survival in untreated primary melanoma tumors, using data collected in an ongoing large P01 study on the Integration of Clinical and Molecular Biomarkers for Melanoma Survival (InterMEL). Here we present preliminary findings on sex, survival, and somatic TMB from 60 Stage II and Stage III primary melanoma tumors, none of which have received immunotherapy using the MSK IMPACT™ next generation sequencing assay. Our preliminary analysis includes 30 patients who died within 5 years (median survival of 31 months) and 30 patients who lived for more than 5 years since diagnosis (median follow-up of 86 months). We found the expected relationship between TMB and better survival in a univariate Cox regression analysis (HR=0.43, 95% CI=0.19 to 0.97, P=0.04), but no evidence of association between TMB and sex (Wilcoxon rank-sum test P=0.7) or any relationship between sex and survival (logrank test P=0.42). Our study is the first to investigate the relationship between sex, tumor mutational burden, and mortality in an early stage primary cohort that has not received immunotherapy. In our small sample, we observed the expected protective effect of TMB on survival, but no evidence of gender differences in TMB or survival. This is surprising given the robust, consistent, and well-documented female survival advantage (Roh et al., 2015; de Vries et al., 2008), and merits further investigation. Our results are an important first step to increasing our understanding of the relationship between mutational burden, survival, and biological sex. References Roh, M.R., Eliades, P., Gupta, S., Grant-Kels, J.M., and Tsao, H. (2015). Cutaneous melanoma in women. Int. J. Womens Dermatol. 1, 21–25. de Vries, E., Nijsten, T.E.C., Visser, O., Bastiaannet, E., van Hattem, S., Janssen-Heijnen, M.L., and Coebergh, J.-W.W. (2008). Superior survival of females among 10 538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann. Oncol. 19, 583–589. Citation Format: Matthew R. Schwartz, Li Luo, Marianne Berwick. Sex, mutations, and mortality in early stage melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3419.
Chemical Reactivity-Absorption, Retention, Metabolism, and Elimination of Hexachlorocyclopentadiene
Authors: H. M. Mehendale
Journal: Environmental Health Perspectives (1977)

Hexachlorocyclopentadiene is eliminated from the body efficiently by urinary excretion. Although direct evidence is not available, it appears that expiration may be another important route of elimination. Of the administered dose 9% is excreted in the bile in 1 hr, approximately equal to the amount of fecal excretion in 7 days, suggesting enterohepatic circulation. After a single dose, HCPD decays from the blood biexponentially with a terminal phase half-life of 60 min. Of the tissues analyzed kidney, followed by liver, concentrate HCPD 1 hr or 7 days after exposure to any significant extent. Subcellularly, HCPD is predominantly associated with cytosol fractions of both kidney as well as liver, observations consistent with rapid elimination of HCPD after a single exposure. Preexposure to HCPD (50 mg/kg-day for 3 days) resulted in unaltered blood decay curves and biliary excretion, but increased the concentration in the kidneys after a single subsequent challenge.
MRFIT after 10.5 years
Authors: T. K. Rosborough
Journal: JAMA (1990)

<h3>To the Editor.—</h3> We read with interest the recent article about late results in the Multiple Risk Factor Intervention Trial (MRFIT).<sup>1</sup>We are puzzled by the optimistic conclusions. The authors claim that the data "suggest" a mortality benefit in middle-aged men over a period of about 10 years. This is not supported by their statistics. Even using less stringent one-tailed statistics, the<i>P</i>values for deaths from coronary heart disease, cardiovascular disease, and all causes for the entire 10.5 years were .10 or greater for the differences between the special intervention and the usual care groups. Only for deaths occurring in the years after the trial had ended is there a statistically significant difference in all deaths (but not in deaths from coronary heart disease). We wonder to what extent a comparison of these two groups after the trial has ended is justified, since little information on the behavior of
Breast Cancer
Journal: JAMA (1976)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SHALL THE CALORIES BE FORGOTTEN?
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lowering the perinatal mortality and the prematurity rate; the value of prophylactic thiazides in juveniles
Authors: F. A. Finnerty
Journal: JAMA (1966)

The incidence of toxemia and rates of perinatal mortality and prematurity were compared in 1,340 normal juveniles who received thiazides prophylactically with 1,743 normal juveniles who did not receive thiazides. More than a 10% increase in arterial pressure and albuminuria not due to infection developed in 61 (5%) of the treated patients and 270 (15%) of the nontreated patients. In the 1,340 treated patients the perinatal mortality was 0.7% (one stillbirth plus eight neonatal deaths) and the prematurity rate was 5% (73 infants). In the 1,743 nontreated patients the perinatal mortality was 5% (53 stillbirths plus 11 neonatal deaths) and the prematurity rate was 12% (223 infants). It is concluded that the prophylactic use of thiazides not only protects the mother from toxemia but also significantly reduces perinatal mortality and prematurity.
Myelodysplastic Syndrome
Authors: Chi Van Dang
Journal: JAMA (1992)

<h3>CASE PRESENTATION</h3> —Lawrence Nair, MD A 54-YEAR-OLD white man was referred to The Johns Hopkins Hospital because of refractory anemia. In 1988, anemia and neutropenia were noted, and in July 1990 he was admitted to another hospital, with a hemoglobin level of 55 g/L. Bone marrow biopsy revealed myeloid hyperplasia, and the proportion of blast cells was 0.02 to 0.03. The patient was thought to have a myelodysplastic disorder, and was given weekly transfusions of packed red blood cells (RBCs). In August 1990, the patient was referred to the National Institutes of Health for a second opinion. Bone marrow biopsy was repeated, and the findings were thought to be consistent with myelofibrosis. He was started on a trial course of danazol, as well as cyanocobalamin, pyridoxine hydrochloride, and folic acid. However, in September, the patient was readmitted with severe pain in the left upper quadrant of the abdomen, and a
Disk Battery Ingestion
Authors: Ken Kulig
Journal: JAMA (1983)

AS THE use of small, flat, disk batteries as energy sources for cameras and other electronic devices has increased, the incidence of reported cases of ingested disk batteries has also increased. Although clinical experience would seem to indicate that in the majority of these cases the battery is eventually passed through the gastrointestinal (GI) tract without incident, in a few patients the battery has been known to leak in the GI tract and result in a serious toxic reaction. We report the case of a child who absorbed mercury from a swallowed disk battery that opened in the large bowel and released mercuric oxide. <h3>Report of a Case</h3> An 18-month-old girl was suspected of having ingested a brand-new mercury photo battery when the opened package was found. Two hours after the battery was noticed to be missing, an abdominal roentgenogram was obtained, which demonstrated the intact battery in the child's
Erratum: Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
Authors: D C Phillips, Y Xiao, L T Lam, E Litvinovich, L Roberts-Rapp, A J Souers, J D Leverson
Journal: Blood Cancer Journal (2016)

Correction to: Blood Cancer Journal (2015) 5, e368; doi:10.1038/bcj.2015.88; published online 13 November 2015 Following the publication of this article, the authors noted the following errors: 1. The final sentence in the legend of Figure 1 should be 'Data are presented as the mean±s.e.m. of one-two experiments each in triplicate'.
THE PROTEOLYTIC INTRACELLULAR FERMENTS AND AUTOLYSIS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Statement: Conflict of Interest
Authors: International Committee of Medical Journal Editors
Journal: Annals of Internal Medicine (1993)

Editorials15 April 1993Statement: Conflict of InterestInternational Committee of Medical Journal EditorsInternational Committee of Medical Journal EditorsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-8-199304150-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail During its most recent meeting, 14-15 January 1993 in London, the International Committee of Medical Journal Editors approved the following statement on conflict of interest in peer review and publication in medical journals.Conflict of interest for a given manuscript exists when a participant in the peer review and publication processauthor, reviewer, and editorhas ties to activities that could inappropriately influence his or her judgment, regardless of whether judgment is, in fact, affected. Financial relationships with industry (for example, employment, consultancies, stock ownership, honoraria, expert testimony), either directly or through immediate family, are usually considered the most important conflicts of ... Author, Article, and Disclosure InformationAffiliations: Members of the committee are Marcia Angell (The New England Journal of Medicine), Linda Hawes Clever (Western Journal of Medicine), Lois Ann Colaianni (Index Medicus), Robert Fletcher and Suzanne Fletcher (Annals of Internal Medicine), Jill Forrest (Medical Journal of Australia), Robin Fox (The Lancet), Jerome Kassirer (The New England Journal of Medicine), Richard Glass and George Lundberg (Journal of the American Medical Association),Magne Nylenna (Tidsskrift for den Norske Laegeforening), Richard Robinson (The New Zealand Medical Journal), Richard Smith (British Medical Journal), Bruce Squires (Canadian Medical Association Journal), Laurel Thomas (Medical Journal of Australia), and Patricia Woolf (Princeton University). Please address comments to Kathleen Case (ICMJE Secretariat; Annals of Internal Medicine). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byResearch transparency promotion by surgical journals publishing randomised controlled trials: a surveyNormas para la bibliografía médicaRequirements for Medical Writing: Reporting Bariatric Surgical OutcomesWho controls the controllers? – Authors' replyStyle and substance in Gastrointestinal EndoscopyPolicies, practices, and attitudes of north american medical journal editorsLitigation-related Research 15 April 1993Volume 118, Issue 8Page: 646-647KeywordsConflicts of interestDecision makingPeer reviewResearch reporting guidelines ePublished: 15 August 2000 Issue Published: 15 April 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Principles of educational outreach ('academic detailing') to improve clinical decision making
Authors: S. B. Soumerai
Journal: JAMA (1990)

With the efficacy and costs of medications rising rapidly, it is increasingly important to ensure that drugs be prescribed as rationally as possible. Yet, physicians' choices of drugs frequently fall short of the ideal of precise and cost-effective decision making. Evidence indicates that such decisions can be improved in a variety of ways. A number of theories and principles of communication and behavior change can be found that underlie the success of pharmaceutical manufacturers in influencing prescribing practices. Based on this behavioral science and several field trials, it is possible to define the theory and practice of methods to improve physicians' clinical decision making to enhance the quality and cost-effectiveness of care. Some of the most important techniques of such "academic detailing" include (1) conducting interviews to investigate baseline knowledge and motivations for current prescribing patterns, (2) focusing programs on specific categories of physicians as well as on their opinion leaders, (3) defining clear educational and behavioral objectives, (4) establishing credibility through a respected organizational identity, referencing authoritative and unbiased sources of information, and presenting both sides of controversial issues, (5) stimulating active physician participation in educational interactions, (6) using concise graphic educational materials, (7) highlighting and repeating the essential messages, and (8) providing positive reinforcement of improved practices in follow-up visits. Used by the nonprofit sector, the above techniques have been shown to reduce inappropriate prescribing as well as unnecessary health care expenditures. (<i>JAMA</i>. 1990;263:549-556)
IDH1 mutation in prostate cancer: R132H and beyond.
Authors: Amber Lea Flaherty, Jingsong Zhang, Jamie Teer
Journal: Journal of Clinical Oncology (2014)

e16024 Background: Previous reports on mutations in the isocitrate dehydrogenase 1 (IDH1) gene in prostate cancer focused on the evolutionarily conserved residue R132 located in the substrate binding site of IDH1. One study reported R132 mutations in 2/75 (2.7%) prostate cancers, whereas the other study did not find R132 mutation in 4 prostate cancers or the 2 prostate cancer cell lines. We therefore studied the IDH1 mutations in our prostate cancer targeted exon sequencing database. Methods: Targeted exon sequencing was performed on 52 samples of prostate cancers as part of Moffitt Cancer Center’s Total Cancer Care initiative. The coverage was set to be at least 50 fold. 51/52 samples are treatment naïve primary prostate cancer obtained during radical prostatectomy and 1 sample is a treatment naïve prostate cancer brain metastasis. Comparison was made to the 1,000 genomes project to exclude inherited polymorphisms, and Polyphen and COSMIC were used to assess mutation importance. Results: (1) Among the frequent gene mutations in metastatic prostate cancer, only a missense mutation in the androgen receptor (H875Y) was identified in the treatment naive brain metastasis. This H875Y has been linked to promiscuous androgen receptor. (2) 1/51 (2%) primary prostate cancers harbor the R132H mutation, which is known to generate the oncometabolite, (R)-2-hydroxylutarate. (3) Another prostate cancer had T325M mutation and is predicted to be
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).
Authors: Timothy J. Hobday, Rui Qin, Diane Lauren Reidy, Malcolm J Moore, Jonathan R. Strosberg, Andreas Kaubisch, Manisha H. Shah, Hedy Lee Kindler, Heinz-Josef Lenz, Helen X. Chen, Charles Erlichman
Journal: Journal of Clinical Oncology (2012)

260 Background: Recent placebo-controlled phase III trials of the mTOR inhibitor everolimus and the VEGF/ PDGF receptor inhibitor sunitinib in PNET noted improved progression-free survival (PFS). However, objective response rates (RR) with these agents are &lt;10%. Preclinical studies suggest enhanced anti-tumor effects with combined mTOR and VEGF targeted therapy. Methods: We conducted a phase II trial of the mTOR inhibitor TEM (25 mg IV q week) and the VEGF-A monoclonal antibody BEV (10 mg/kg IV q 2 weeks) in patients (pts) with well or moderately differentiated PNET and progressive disease by RECIST within 7 months of study entry. Co-primary endpoints were RR and 6-month PFS. Planned enrollment is 50 patients, with interim analysis after the first 25 evaluable pts. Pts had no prior mTOR or VEGF targeted agents, ECOG PS 0-1, and adequate hematologic and organ function. Continued octreotide was allowed, but not required. Prior interferon, embolization, and ≤ 2 chemotherapy regimens were allowed. Results: Confirmed PR was documented in 11 of the first 25 (44%) evaluable patients. 20 of 25 (80%) patients were progression-free at 6 months. Both endpoints exceeded pre-defined criteria to continue enrollment. For 35 evaluable patients, the most common grade 3-4 adverse events attributed to therapy were leukopenia (12%), hypertension (12%), hyperglycemia (12%), mucositis (9%), and fatigue (9%). Conclusions: The combination of TEM/BEV has substantial activity in a multi-center phase II trial with RR of 44%, well in excess of single targeted agents in PNET. 6-month PFS was a notable 80% in a population of patients with RECIST criteria progression within 7 months of study entry. Accrual is ongoing. Supported by NCI N01 Contracts: 662205, 62203, 62208, 62209, 62206, 62204, 62207, 62201.